logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Oral calcitonin for osteoarthritis of knee

< Back

Oral calcitonin for osteoarthritis of knee

Drugs

Musculoskeletal

August 2010


Oral calcitonin (oral salmon calcitonin, salmon calcitonin, SMC-021) is an oral formulation of salmon calcitonin with 5-CNAC, a unimolecular enhancer of gastrointestinal absorption of the peptide hormone. Salmon calcitonin inhibits osteoclast activity, strengthens subchondral bone and has chondroprotective, chondroanabolic and musculoskeletal analgesic effects. It is intended both as a substitute and an addition to current symptom modifying drugs for the treatment of OA of the knee in men and postmenopausal women. Oral calcitonin is administered orally at 0.8mg twice daily.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts